ASAndrew David Seidman

Andrew David Seidman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew David Seidman has a total of 311 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment patterns and clinical outcomes of patients with HER2-positive T1micN0 breast cancer: a single-center analysis

    by Celine Yeh, Rachel Han, Abha Kulkarni, Charlie White, Yuan Chen, Matthew G. Hanna, Edi Brogi, Andrew D. Seidman

    We conducted a retrospective analysis of 213 patients with HER2+ T1micN0 breast cancer. Patients with ≥5 foci of microinvasion received more aggressive treatment with higher rates of sentinel lymph node biopsy and adjuvant chemotherapy/HER2-targeted therapy (CT/H2TT) than patients with 1–4 foci. We did not detect significant differences in invasive disease-free survival between patients with 1–4 and ≥5 foci, or between patients with ≥5 foci who did and did not receive adjuvant CT/H2TT.


  • Clinicopathological features of microinvasive lobular carcinoma

    by Rachel Han, Atif A Hashmi, Hannah Y Wen, Melissa Murray, M Gabriela Kuba, Andrew D Seidman, Monica Morrow, Edi Brogi

    Aims: Microinvasive lobular carcinoma (MILC) is a rare form of minimally invasive carcinoma with incomplete pathological and clinical characterisation. We sought to identify the clinical and pathological features of MILC diagnosed at our institution between 2009 and 2023.Methods and results: Patient demographic, pathological and clinical data were collected. Patients with a prior or synchronous history of invasive carcinoma were excluded. The study cohort included 30 female patients with a median age of 53 years. The most common imaging target was microcalcifications (63%). MILC was diagnosed on biopsy alone in three cases (10%), excision alone in 22 cases (73%) and on both biopsy and excision in five cases (17%). Most MILCs were unifocal (57%). MILCs were associated with classic lobular carcinoma in‐situ (LCIS) in 90% of cases, florid LCIS in 27% and pleomorphic LCIS in 17%. None of 21 patients (70%) who underwent sentinel lymph node biopsy had lymph node involvement. Biomarker status was available in 16 (53%) MILC; 12 were oestrogen receptor+/progesterone receptor+/human epidermal growth factor receptor 2‐ (ER+/PR+/HER2–), two were ER+/PR–/HER2–, one was ER−/PR−/HER2+ and one was ER−/PR−/HER2 2+ but insufficient for fluorescence in‐situ hybridisation (FISH) analysis. Median follow‐up was 49 months. A patient with MILC at the excision margin of the index excision specimen did not undergo re‐excision; 15 months later she developed an ipsilateral invasive carcinoma with ductal and lobular features and died of disease 73 months after initial diagnosis. All other 29 patients are alive with no evidence of disease.Conclusion: MILC is a relatively indolent tumour arising in classic and variant LCIS, with a low risk of axillary or distant metastases.


  • Open Access

    Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab

    by S. M. Chew, E. Ferraro, Y. Chen, A. V. Barrio, D. Kelly, S. Modi, A. D. Seidman, H. Wen, E. Brogi, M. Robson, et al.

    Patients with HER2(+) early breast cancer (EBC) receiving neoadjuvant systemic therapy (NAST) have poorer outcomes if they have residual disease (RD). We analyzed IDFS and brain metastasis (BM) rates in patients with HER2(+) EBC treated with NAST and report the outcomes of patients with HER2(−) RD. Patients with HER2(+) EBC who received NAST between 1 Jan 2019 and 31 Jan 2022 were reviewed. IDFS was defined as the time from surgery until first occurrence of invasive breast cancer recurrence, distant recurrence, or death from any cause. The total cohort was 594 patients. pCR (ypT0/isN0) was achieved in 325(55%) and RD was seen in 269(45%) patients. In 269 patients with RD, 45(17%) did not have HER2 retesting and were excluded. In the remaining 224 patients, 143(64%) were HER2(+) and 81(36%) were HER2(−). With a median follow up of 24 months, 8 patients developed BM at initial recurrence, 4/325(1.2%) with pCR and 4/143(2.8%) with HER2(+) RD. IDFS events occurred in 22/594(3%) patients; 14/269(5%) in RD and 8/325(2%) in pCR (p = 0.04). There was no difference in IDFS between 9/143(6%) patients with HER2(+) RD or 5/81(6%) with HER2(−) RD (p = 0.10). Patients with RD had higher IDFS events than those with pCR. In those with RD, 36% lost HER2(+) status; IDFS events appeared similar in those with HER2(+) RD versus those with HER2(−) RD. The BM events seen in those with RD and pCR highlights the need for more effective therapy in NAST and adjuvant setting to minimize BM risk.


  • Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes

    by Sonya M. Chew, Emanuela Ferraro, Anton Safonov, Yuan Chen, Daniel Kelly, Pedram Razavi, Mark Robson, Andrew D. Seidman


  • Open Access

    Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis

    by Nelson S. Moss, Jolene M. Singh, Anne S. Reiner, Joshua Z. Drago, Shanu Modi, Andrew D. Seidman, Sarat Chandarlapaty, Dara S. Ross

    The HER2-directed antibody-drug conjugate trastuzumab deruxtecan is active against lower levels of HER2 expression than prior-generation therapies. The rate of HER2 expression in brain metastases among patients with initially HER2-null breast cancer is undefined, and receptor discordance in advanced breast cancer with brain metastases may underestimate CNS response potential in the absence of brain metastasis sampling. In this cohort study including 136 patients with 401 samples scored according to ASCO/CAP guidelines, 15/28 patients (54%) with HER2-null primary breast cancer have detectable HER2 expression in subsequently resected brain metastases, a significant discordant population.


  • Open Access

    Invasive Disease Free Survival and Brain Metastasis Rates in Patients Treated with Neoadjuvant Chemotherapy with Trastuzumab and Pertuzumab

    by Chau Dang, Sonya Chew, Emanuela Ferraro, Yuan Chen, Andrea Barrio, Daniel Kelly, Shanu Modi, Andrew Seidman, Hannah Wen, Edi Brogi, et al.

    Background: Patients (pts) with human epidermal growth factor receptor 2 (HER2) positive (+) early breast cancer (EBC) receiving neoadjuvant systemic therapy (NAST) have poorer outcomes if they have residual disease (RD) after surgery. HER2 negative (-) RD has been reported in 1/3 of pts after NAST. The KATHERINE trial suggests that pts with HER2(-) RD (8%) have better invasive disease free survival (IDFS) with adjuvant (adj) trastuzumab emtansine (T-DM1) versus trastuzumab (H) alone. However, only 18% of the pts enrolled in the trial received NAST with trastuzumab and pertuzumab (HP). We aimed to analyze IDFS and brain metastasis (BM) rates in pts with HER2(+) EBC in a modern population homogenously treated with NAST. We also report the incidence of pts with HER2(-) RD and their outcomes.Methods: Clinicopathologic data for pts with HER2(+) EBC who received NAST between 1 Jan 2019 and 31 Jan 2022 were reviewed. External assessment of HER2 status before NAST was allowed. HER2 status of the surgical specimens with RD were assessed internally at our center. IDFS was defined as the time from surgery until first occurrence of invasive breast cancer recurrence, distant recurrence, or death from any cause.Results: The total cohort was 594 pts. 456 (77%) and 138 (23%) received antracycline-taxane and taxane based chemotherapy, respectively during NAST. 587 (99%) received HP and 7 (1%) received H alone. NAST was completed by 566 (95%) of pts. pCR (ypT0/isN0) was achieved in 325 (55%) and RD was seen in 269 (45%) pts. In 269 pts with RD, 45 (17%) did not have HER2 retesting and were excluded from the final analysis. In the remaining 224 pts, 143 (64%) were HER2(+) and 81 (36%) were HER2(-). In the 143 pts with HER2(+) RD, adj T-DM1, HP, H alone and no HER2 directed therapy were received by 121 (85%), 16 (11%), 1 (1%) and 5 (3%) of pts, respectively. In the 81 pts with HER2(-) RD, adj T-DM1, HP, H alone and no HER2 directed therapy were received by 45 (56%), 27 (33%), 3 (4%) and 6 (7%) of pts, respectively. With a median follow up of 24 months, 8 patients developed BM at initial recurrence, 4/325 (1.2%) with pCR and 4/143 (2.8%) with HER2(+) RD. None of the pts who developed BM had HER2(-) RD. IDFS events occurred in 22/594 (3%) pts. Pts with RD had a higher likelihood of having an IDFS event, 14/269 (5%) in RD and 8/325 (2%) in pCR (p = 0.04). In the evaluable 224 pts with RD, there was no difference in IDFS between 9/143 (6%) pts with HER2(+) RD or 5/81 (6%) with HER2(-) RD (p = 0.10).Conclusions: At a single center, in pts who predominantly received HP with chemotherapy as NAST, pts with RD had higher IDFS events than those with pCR. In those with RD, 36% lost HER2(+) status; IDFS events appeared similar in those with HER2(+) RD versus those with HER2(-) RD. The HER2 loss rate is higher than reported in KATHERINE possibly due to majority of pts receiving effective dual HP as NAST. The BM events seen in those with RD and pCR highlights the need for more effective therapy in NAST and adj setting to minimize BM risk.

  • New strategies for the treatment of breast cancer with leptomeningeal metastasis

    by Sonya M. Chew, Andrew D. Seidman

    Purpose of review: Leptomeningeal metastasis is a complication of metastatic breast cancer that has a rising incidence likely due to the increased availability of novel systemic therapies, which have improved survival with better extracranial disease control but with limited intracranial efficacy. A poor prognosis of less than 6 months has historically been associated with leptomeningeal metastasis and it is often an exclusion factor for enrollment in clinical trials. There are limited evidence-based data supporting use of therapeutics in leptomeningeal metastasis patients and recommendations are largely derived from retrospective reports and small prospective studies. However, in recent years, there has been a surge in effective modern therapeutics with promising intracranial activity. Recent findings: The study aims to review the most recent updates in the management of leptomeningeal metastasis in breast cancer. We discuss the effectiveness and limitations of intrathecal administration, predictive biomarkers in the cerebrospinal fluid, proton radiation therapy and promising new systemic therapies such as antibody drug conjugates. Summary: Ongoing development of clinical trials that allow inclusion of leptomeningeal metastasis are essential for establishing efficacy potential and discovering new treatment options in this population of great unmet need.


  • Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases

    by S. Chew Minmin, A. Bacotti, Y. Chen, C. Anders, M. Sambade, A. M. Deal, D. Trembath, M. J. McKee, E. Brogi, A. D. Seidman

    Purpose Tumor-infiltrating lymphocytes (TILs) have been positively correlated with response to systemic therapy for triple-negative and HER2 + subtypes and improved clinical outcomes in early breast cancer (BC). Less is known about TILs in metastatic sites, particularly brain metastases (BM), where unique immune regulation governs stromal composition. Reactive glial cells actively participate in cytokine-mediated T cell stimulation. The impact of prior medical therapy (chemotherapy, endocrine, and HER2-targeted therapy) on the presence of TILs and gliosis in human breast cancer brain metastases (BCBM) has not been previously reported. Methods We examined prior treatment data for 133 patients who underwent craniotomy for resection of BMs from the electronic medical record. The primary endpoint was overall survival (OS) from the time of BM diagnosis. We examined the relationship between prior systemic therapy exposure and the histologic features of gliosis, necrosis, hemorrhage, and lymphocyte infiltration (LI) in BCBMs resected at subsequent craniotomy in univariate analyses. Results Complete treatment data were available for 123 patients. BCBM LI was identified in 35 of 116 (30%) patients who had received prior systemic treatment versus 5 of 7 (71.4%) who had not {significant by Fisher’s exact test p = 0.045}. There were no statistically significant relationships between prior systemic therapy and the three other histologic variables examined. Conclusions This observation suggests that systemic therapy may interfere with the immune response to BCBMs and cause exhaustion of anti-tumor immunity. This motivates clinical investigation of strategies to enhance LI for therapeutic benefit to improve outcomes for patients with BCBMs.


  • Breast Cancer Brain Metastases: Achilles’ Heel in Breast Cancer Patients’ Care

    by Emanuela Ferraro, Andrew D. Seidman

    Brain metastases (BM) significantly affect the prognosis as well as the quality of life of breast cancer (BC) patients. Although advancements in neurosurgical and radiotherapy techniques improve local control and symptom management, BM remains associated with a poor prognosis. In addition, the efficacy of currently approved systemic therapies in central nervous system (CNS) compartment is still limited, especially after progression on local therapy. The blood-brain barrier (BBB) has been recognized as a mechanism of primary resistance to many chemotherapeutic agents and targeted therapies due to low drug penetration. Other mechanisms of primary and secondary resistance are still unclear and may vary across the BC subtypes. New small molecules have demonstrated efficacy in BM, in particular for the HER2-positive subtype, with a benefit in survival. A new era has begun in the field of BM, and many trials specifically designed for this population are currently ongoing. The BC research community needs to address this call with the final aim of improving the efficacy of systemic therapy in CNS compartment and ultimately preventing the occurrence of BM. Keywords Brain metastasis Central nervous system metastases Breast cancer Triple negative breast cancer HER2-positive breast cancer


  • A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging

    by Aki Morikawa, Milan Grkovski, Sujata Patil, Komal L. Jhaveri, Kendrick Tang, John L. Humm, Andrei Holodny, Kathryn Beal, Heiko Schöder, Andrew D. Seidman

    Purpose Sorafenib has demonstrated anti-tumor efficacy and radiosensitizing activity preclinically and in breast cancer. We examined sorafenib in combination with whole brain radiotherapy (WBRT) and explored the [18F] 3′deoxy-3′-fluorothymidine (FLT)-PET as a novel brain imaging modality in breast cancer brain metastases. Methods A phase I trial of WBRT + sorafenib was conducted using a 3 + 3 design with safety-expansion cohort. Sorafenib was given daily at the start of WBRT for 21 days. The primary endpoints were to determine a maximum tolerated dose (MTD) and to evaluate safety and toxicity. The secondary endpoint was CNS progression-free survival (CNS-PFS). MacDonald Criteria were used for response assessment with a correlative serial FLT-PET imaging study. Results 13 pts were evaluable for dose-limiting toxicity (DLT). DLTs were grade 4 increased lipase at 200 mg (n = 1) and grade 3 rash at 400 mg (n = 3). The MTD was 200 mg. The overall response rate was 71%. Median CNS-PFS was 12.8 months (95%CI: 6.7-NR). A total of 15 pts (10 WBRT + sorafenib and 5 WBRT) were enrolled in the FLT-PET study: baseline (n = 15), 7–10 days post WBRT (FU1, n = 14), and an additional 12 week (n = 9). A decline in average SUVmax of ≥ 25% was seen in 9/10 (90%) of WBRT + sorafenib patients and 2/4 (50%) of WBRT only patients. Conclusions Concurrent WBRT and sorafenib appear safe at 200 mg daily dose with clinical activity. CNS response was favorable compared to historical controls. This combination should be considered for further efficacy evaluation. FLT-PET may be useful as an early response imaging tool for brain metastases. Trial and Clinical Registry Trial registration numbers and dates: NCT01724606 (November 12, 2012) and NCT01621906 (June 18, 2012).